Regeneron Pharmaceuticals (STU:RGO) Research & Development: €5,213 Mil (TTM As of Mar. 2026)


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
87 GF Score
Price €554.60
GF Value €788.02
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Research & Development?

Regeneron Pharmaceuticals STU:RGO +1.76% 87 Research & Development is €5,213 Mil as of Mar. 2026. GuruFocus rates STU:RGO with a GF Score™ of 87/100 and a GF Value™ of €788.02 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Regeneron Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was €1,335 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €5,213 Mil.

Regeneron Pharmaceuticals  (STU:RGO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Regeneron Pharmaceuticals Research & Development Related Terms

Regeneron Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Research & Development Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,531.19 3,391.32 4,070.56 4,901.06 4,996.07

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,227.85 1,232.61 1,256.70 1,388.69 1,335.13
STU:RGO
87GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5,213 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €5,213 Mil mean?
Regeneron Pharmaceuticals (STU:RGO) has a Research & Development of €5,213 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Research & Development too high?
Regeneron Pharmaceuticals' current Research & Development is €5,213 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Research & Development compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Research & Development of €5,213 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Research & Development is €5,213 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Significantly Undervalued. The stock's GF Value™ is €788.02, compared to a current price of €554.60 — trading 29.6% below its estimated fair value. The current Research & Development is €5,213 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Research & Development is €5,213 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €554.60 is trading 29.6% below its estimated GF Value™ of €788.02. GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:RGO:

  • Research & Development: €5,213 Mil
  • GF Value™: €788.02 vs. price of €554.60 (29.6% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score

Get the complete analysis for STU:RGO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€554.60
Price
€788.02
GF Value